Thermo Fisher Scientific Inc. (TMO) EV/EBITDA Ratio: 19.72x
Is Thermo Fisher Scientific Inc.’s EV/EBITDA ratio high or low?
Thermo Fisher Scientific Inc.'s EV/EBITDA ratio of 19.72x is in line with its 5-year average of 20.32x, around the middle of its 5-year range (15.37x–24.30x).
The EV/EBITDA ratio for Thermo Fisher Scientific Inc. (TMO) is 19.72x as of Wednesday, June 10, 2026. It is below its 12-month average by 0.09% (19.74x).
TMO EV/EBITDA Ratio Chart
TMO Average EV/EBITDA Ratio Chart
TMO Current vs Average EV/EBITDA Ratio Chart
TMO EV/EBITDA Ratio Metrics
EV/EBITDA RATIO
19.72x
EV/EBITDA RATIO AVG TTM
19.74x
EV/EBITDA RATIO AVG 3Y
20.47x
EV/EBITDA RATIO AVG 5Y
20.32x
EV/EBITDA RATIO AVG 10Y
20.35x
EV/EBITDA RATIO AVG 15Y
18.71x
EV/EBITDA RATIO AVG 20Y
17.78x
CURRENT VS TTM AVG
-0.09%
CURRENT VS 3Y AVG
-3.66%
CURRENT VS 5Y AVG
-2.93%
CURRENT VS 10Y AVG
-3.09%
CURRENT VS 15Y AVG
+5.38%
CURRENT VS 20Y AVG
+10.94%
TMO Competitors' EV/EBITDA Ratio
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 19.72x | 19.74x | 20.47x | 20.32x |
| Amgen Inc. (AMGN) | $183.75B | 13.28x | 13.25x | 14.20x | 13.96x |
| Abbott Laboratories (ABT) | $154.66B | 16.88x | 18.72x | 19.30x | 18.58x |
| Gilead Sciences, Inc. (GILD) | $151.21B | 12.54x | 14.17x | 17.98x | 15.97x |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 39.06x | 52.49x | 59.81x | 55.90x |
| Pfizer Inc. (PFE) | $146.36B | 12.38x | 10.50x | 15.94x | 13.74x |
| Danaher Corporation (DHR) | $130.25B | 21.52x | 23.46x | 23.88x | 22.36x |
| CVS Health Corporation (CVS) | $125.16B | 17.45x | 14.88x | 11.86x | 12.00x |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 10.82x | 9.64x | 16.60x | 15.48x |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 20.92x | 22.99x | 82.30x | 54.94x |
EV/EBITDA vs. its own history
At 19.7, EV/EBITDA is richer than usual — richer than 65% of its 20-year range.
20-year low
6.8
median
18.3
20-year high
48.5
Understanding EV/EBITDA
Enterprise Value (EV) = Market Cap + Total Debt - Cash
EBITDA = Earnings Before Interest, Taxes, Depreciation & Amortization
EV/EBITDA is commonly used for comparing companies because:
- It accounts for debt levels (capital structure neutral)
- It removes effects of different depreciation policies
- It can be compared across countries with different tax rates
- It can remain available when net income is negative, if EBITDA is positive
Thermo Fisher Scientific Inc. EV/EBITDA Ratio Formula & Definition
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Thermo Fisher Scientific Inc. EV/EBITDA Ratio FAQ
- What is the EV/EBITDA ratio for Thermo Fisher Scientific Inc. (TMO)?
- The EV/EBITDA ratio for TMO stock is 19.72x.
- Is Thermo Fisher Scientific Inc.'s EV/EBITDA ratio high or low?
- Thermo Fisher Scientific Inc.'s EV/EBITDA ratio of 19.72x is in line with its 5-year average of 20.32x, around the middle of its 5-year range (15.37x–24.30x).
- What is the TTM average EV/EBITDA ratio for Thermo Fisher Scientific Inc. (TMO)?
- The TTM average EV/EBITDA ratio for TMO stock is 19.74x.
- What is the 3Y average EV/EBITDA ratio for Thermo Fisher Scientific Inc. (TMO)?
- The 3Y average EV/EBITDA ratio for TMO stock is 20.47x.
- What is the 5Y average EV/EBITDA ratio for Thermo Fisher Scientific Inc. (TMO)?
- The 5Y average EV/EBITDA ratio for TMO stock is 20.32x.
- What is the 10Y average EV/EBITDA ratio for Thermo Fisher Scientific Inc. (TMO)?
- The 10Y average EV/EBITDA ratio for TMO stock is 20.35x.
- What is the 15Y average EV/EBITDA ratio for Thermo Fisher Scientific Inc. (TMO)?
- The 15Y average EV/EBITDA ratio for TMO stock is 18.71x.
- What is the 20Y average EV/EBITDA ratio for Thermo Fisher Scientific Inc. (TMO)?
- The 20Y average EV/EBITDA ratio for TMO stock is 17.78x.
Thermo Fisher Scientific Inc. EV/EBITDA Ratio History
| DATE | EV/EBITDA RATIO |
|---|---|
| 2026-06-10 | 19.72x |
| 2026-06-09 | 20.09x |
| 2026-06-08 | 19.27x |
| 2026-06-05 | 19.38x |
| 2026-06-04 | 19.68x |
| 2026-06-03 | 19.41x |
| 2026-06-02 | 19.69x |
| 2026-06-01 | 20.09x |
| 2026-05-29 | 20.04x |
| 2026-05-28 | 19.86x |
| 2026-05-27 | 18.82x |
| 2026-05-26 | 18.55x |
| 2026-05-22 | 18.56x |
| 2026-05-21 | 18.59x |
| 2026-05-20 | 18.67x |
| 2026-05-19 | 18.54x |
| 2026-05-18 | 18.35x |
| 2026-05-15 | 18.22x |
| 2026-05-14 | 18.55x |
| 2026-05-13 | 18.48x |
| 2026-05-12 | 18.93x |
| 2026-05-11 | 18.70x |
| 2026-05-08 | 19.12x |
| 2026-05-07 | 19.43x |
| 2026-05-06 | 19.38x |
| 2026-05-05 | 19.17x |
| 2026-05-04 | 19.04x |
| 2026-05-01 | 19.26x |
| 2026-04-30 | 18.43x |
| 2026-04-29 | 18.01x |
| 2026-04-28 | 18.14x |
| 2026-04-27 | 18.07x |
| 2026-04-24 | 18.13x |
| 2026-04-23 | 18.03x |
| 2026-04-22 | 19.58x |
| 2026-04-21 | 19.93x |
| 2026-04-20 | 19.98x |
| 2026-04-17 | 20.00x |
| 2026-04-16 | 19.65x |
| 2026-04-15 | 20.16x |
| 2026-04-14 | 20.02x |
| 2026-04-13 | 19.59x |
| 2026-04-10 | 18.99x |
| 2026-04-09 | 19.14x |
| 2026-04-08 | 19.24x |
| 2026-04-07 | 18.78x |
| 2026-04-06 | 18.73x |
| 2026-04-02 | 18.84x |
| 2026-04-01 | 18.94x |
| 2026-03-31 | 18.84x |
| 2026-03-30 | 18.47x |
| 2026-03-27 | 18.25x |
| 2026-03-26 | 18.76x |
| 2026-03-25 | 18.82x |
| 2026-03-24 | 18.80x |
| 2026-03-23 | 18.40x |
| 2026-03-20 | 18.28x |
| 2026-03-19 | 18.14x |
| 2026-03-18 | 17.96x |
| 2026-03-17 | 18.23x |
| 2026-03-16 | 18.14x |
| 2026-03-13 | 17.95x |
| 2026-03-12 | 18.33x |
| 2026-03-11 | 18.98x |
| 2026-03-10 | 19.12x |
| 2026-03-09 | 19.45x |
| 2026-03-06 | 19.19x |
| 2026-03-05 | 19.74x |
| 2026-03-04 | 19.54x |
| 2026-03-03 | 19.39x |
| 2026-03-02 | 19.40x |
| 2026-02-27 | 19.82x |
| 2026-02-26 | 19.78x |
| 2026-02-25 | 20.11x |
| 2026-02-24 | 20.17x |
| 2026-02-23 | 20.20x |
| 2026-02-20 | 20.02x |
| 2026-02-19 | 20.16x |
| 2026-02-18 | 20.10x |
| 2026-02-17 | 19.71x |
| 2026-02-13 | 19.81x |
| 2026-02-12 | 19.98x |
| 2026-02-11 | 20.56x |
| 2026-02-10 | 20.98x |
| 2026-02-09 | 21.21x |
| 2026-02-06 | 21.08x |
| 2026-02-05 | 21.07x |
| 2026-02-04 | 21.83x |
| 2026-02-03 | 21.99x |
| 2026-02-02 | 22.38x |
| 2026-01-30 | 22.27x |
| 2026-01-29 | 22.73x |
| 2026-01-28 | 23.26x |
| 2026-01-27 | 23.79x |
| 2026-01-26 | 23.88x |
| 2026-01-23 | 23.85x |
| 2026-01-22 | 24.30x |
| 2026-01-21 | 24.20x |
| 2026-01-20 | 23.62x |
| 2026-01-16 | 23.61x |
| 2026-01-15 | 23.81x |
| 2026-01-14 | 23.72x |
| 2026-01-13 | 23.22x |
| 2026-01-12 | 23.50x |
| 2026-01-09 | 23.62x |
| 2026-01-08 | 23.20x |
| 2026-01-07 | 23.56x |
| 2026-01-06 | 23.68x |
| 2026-01-05 | 23.36x |
| 2026-01-02 | 22.74x |
| 2025-12-31 | 22.30x |
| 2025-12-30 | 22.44x |
| 2025-12-29 | 22.49x |
| 2025-12-26 | 22.35x |
| 2025-12-24 | 22.29x |
| 2025-12-23 | 22.32x |
| 2025-12-22 | 22.18x |
| 2025-12-19 | 21.91x |
| 2025-12-18 | 21.73x |
| 2025-12-17 | 21.74x |
| 2025-12-16 | 21.99x |
| 2025-12-15 | 22.18x |
| 2025-12-12 | 22.06x |
| 2025-12-11 | 22.28x |
| 2025-12-10 | 22.11x |
| 2025-12-09 | 21.76x |
| 2025-12-08 | 21.93x |
| 2025-12-05 | 22.08x |
| 2025-12-04 | 22.16x |
| 2025-12-03 | 22.34x |
| 2025-12-02 | 22.33x |
| 2025-12-01 | 22.49x |
| 2025-11-28 | 22.68x |
| 2025-11-26 | 22.76x |
| 2025-11-25 | 22.91x |
| 2025-11-24 | 22.52x |
| 2025-11-21 | 22.57x |
| 2025-11-20 | 22.08x |
| 2025-11-19 | 22.11x |
| 2025-11-18 | 22.19x |
| 2025-11-17 | 21.89x |
| 2025-11-14 | 22.28x |
| 2025-11-13 | 22.33x |
| 2025-11-12 | 22.59x |
| 2025-11-11 | 22.54x |
| 2025-11-10 | 22.20x |
| 2025-11-07 | 22.07x |
| 2025-11-06 | 21.85x |
| 2025-11-05 | 21.91x |
| 2025-11-04 | 21.83x |
| 2025-11-03 | 21.82x |
| 2025-10-31 | 21.90x |
| 2025-10-30 | 21.13x |
| 2025-10-29 | 21.20x |
| 2025-10-28 | 21.18x |
| 2025-10-27 | 21.38x |
| 2025-10-24 | 21.67x |
| 2025-10-23 | 21.65x |
| 2025-10-22 | 21.50x |
| 2025-10-21 | 21.19x |
| 2025-10-20 | 20.72x |
| 2025-10-17 | 20.56x |
| 2025-10-16 | 20.49x |
| 2025-10-15 | 20.19x |
| 2025-10-14 | 20.12x |
| 2025-10-13 | 20.08x |
| 2025-10-10 | 20.09x |
| 2025-10-09 | 20.42x |
| 2025-10-08 | 20.47x |
| 2025-10-07 | 20.57x |
| 2025-10-06 | 20.72x |
| 2025-10-03 | 20.70x |
| 2025-10-02 | 20.10x |
| 2025-10-01 | 20.29x |
| 2025-09-30 | 18.77x |
| 2025-09-29 | 18.01x |
| 2025-09-26 | 18.08x |
| 2025-09-25 | 17.92x |
| 2025-09-24 | 18.21x |
| 2025-09-23 | 18.26x |
| 2025-09-22 | 18.44x |
| 2025-09-19 | 18.59x |
| 2025-09-18 | 18.64x |
| 2025-09-17 | 18.36x |
| 2025-09-16 | 18.63x |
| 2025-09-15 | 18.42x |
| 2025-09-12 | 18.59x |
| 2025-09-11 | 18.98x |
| 2025-09-10 | 18.49x |
| 2025-09-09 | 18.68x |
| 2025-09-08 | 18.86x |
| 2025-09-05 | 19.02x |
| 2025-09-04 | 18.92x |
| 2025-09-03 | 18.76x |
| 2025-09-02 | 18.85x |
| 2025-08-29 | 19.03x |
| 2025-08-28 | 18.93x |
| 2025-08-27 | 18.87x |
| 2025-08-26 | 18.89x |
| 2025-08-25 | 18.96x |
| 2025-08-22 | 19.27x |
| 2025-08-21 | 18.73x |
| 2025-08-20 | 19.10x |
| 2025-08-19 | 19.21x |
| 2025-08-18 | 18.85x |
| 2025-08-15 | 18.90x |
| 2025-08-14 | 18.77x |
| 2025-08-13 | 18.76x |
| 2025-08-12 | 18.52x |
| 2025-08-11 | 18.02x |
| 2025-08-08 | 17.97x |
| 2025-08-07 | 17.77x |
| 2025-08-06 | 17.57x |
| 2025-08-05 | 18.15x |
| 2025-08-04 | 18.16x |
| 2025-08-01 | 18.04x |
| 2025-07-31 | 17.90x |
| 2025-07-30 | 18.22x |
| 2025-07-29 | 18.38x |
| 2025-07-28 | 18.47x |
| 2025-07-25 | 18.25x |
| 2025-07-24 | 18.14x |
| 2025-07-23 | 17.87x |
| 2025-07-22 | 16.59x |
| 2025-07-21 | 15.85x |
| 2025-07-18 | 16.17x |
| 2025-07-17 | 16.51x |
| 2025-07-16 | 16.22x |
| 2025-07-15 | 16.28x |
| 2025-07-14 | 16.52x |
| 2025-07-11 | 16.83x |
| 2025-07-10 | 16.69x |
| 2025-07-09 | 16.34x |
| 2025-07-08 | 16.54x |
| 2025-07-07 | 16.30x |
| 2025-07-03 | 16.65x |
| 2025-07-02 | 16.60x |
| 2025-07-01 | 16.39x |
| 2025-06-30 | 15.87x |
| 2025-06-27 | 15.96x |
| 2025-06-26 | 16.09x |
| 2025-06-25 | 16.04x |
| 2025-06-24 | 15.83x |
| 2025-06-23 | 15.70x |
| 2025-06-20 | 15.62x |
| 2025-06-18 | 15.44x |
| 2025-06-17 | 15.37x |
| 2025-06-16 | 15.85x |
| 2025-06-13 | 15.78x |
| 2025-06-12 | 16.19x |
| 2025-06-11 | 16.18x |
| 2025-06-10 | 16.16x |
| 2025-06-09 | 15.97x |
| 2025-06-06 | 15.75x |
| 2025-06-05 | 15.63x |
| 2025-06-04 | 15.81x |
| 2025-06-03 | 15.69x |
| 2025-06-02 | 15.57x |
| 2025-05-30 | 15.78x |
| 2025-05-29 | 15.81x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Marc N. Casper